Sinobiomed Inc. (OTCBB: SOBM) announced on May 14 that it is going to launch the Phase II Clinical Trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in Q3 2008.

Sinobiomed will conduct the trial in collaboration with Mahidol University in Bangkok, Thailand. The study site is located in Thailand's Ratchaburi Province, approximately 200 km from Bangkok near the Myanmar border.

The Phase I Clinical Trial showed that PfCP2.9 had strong ability to generate an immune response (immunogenicity) with only mild adverse effects, and worked out the optimal dose levels and vaccination schedule required for the next trial.

In January 2008, Sinobiomed was approved to receive grants from the Chinese government funding of CNY 9 million (US$1.24 million) to undertake the Phase II clinical trial of its recombinant malaria vaccine in epidemic areas.